This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Philadelphia, PA.,– Brainsway® Ltd.(TASE: BRIN), a leading company in the development of revolutionary brain disorder treatments, today announced that Dr. Aron Tendler, M.D. will assume the role of Chief Medical Officer (CMO) for the company. Dr. Tendler brings years of experience in the treatment of mental disorders as a psychiatrist, and has been using Brainsway Deep TMS for treating depression over the past six years. He has participated in numerous Deep TMS clinical trials, including studies assessing the efficacy of the technology for treatment of depression, bipolar disorder, smoking cessation, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD). In this role, Dr. Tendler will establish and drive the clinical vision of the company, providing executive medical leadership, motivation and guidance to Brainsway’s providers. The role will also include the execution and implementation of leadership strategies, including collaborative clinical programs with strategic business partners.
“Dr. Tendler’s in-depth expertise in our field will help guide our medical team and reinforce Brainsway’s position as a leader in the treatment of brain disorders,” said Dr. Guy Ezekiel, President and CEO of Brainsway. “His commitment to improving mental health treatment makes him the ideal candidate for the position of CMO, and we are excited to have one of the world’s leading experts in transcranial magnetic stimulation as part of our executive team.”
Deep TMS involves the use of a helmet that generates magnetic fields – similar in amplitude to those used in magnetic resonance imaging (MRI) systems – to briefly stimulate the targeted brain area. The therapy requires only 20-minute daily sessions over a course of four to six weeks. After each session, patients can return home independently and resume their normal routines. Open label and double blind placebo controlled studies have demonstrated the treatment to be very effective. Post-marketing results indicate response rate of approximately 70 percent and a remission rate of 40 to 50 percent.
“Brainsway’s Deep TMS offers hope to patients who have been failed by multiple medications, it is the most tolerable efficacious treatment for treatment resistant depression” said Dr. Tendler. “I have seen rewarding results for Deep TMS in my own clinic, and am committed to helping the executive team drive Brainsway’s growth in the United States and rest of the world, by expanding our research initiatives and increasing adoption of Deep TMS among qualified physicians.”
Dr. Tendler received a B.A. summa cum laude from Yeshiva University, an M.D. with distinction in research from SUNY Downstate Medical Center, trained for two years in internal medicine and psychiatry at Tulane University and completed a residency in Psychiatry at the University of Chicago where he was the consultation liaison chief resident and psychosomatic medicine course director. He trained in General and Behavioral Sleep medicine at Rush University Hospital. In 2006 Dr. Tendler entered private practice, and it has grown to include three TMS centers. He is board certified in Psychiatry and Sleep Medicine.
Brainsway is a leading company dedicated to developing breakthrough brain disorder treatments. Brainsway’s Deep TMS (Transcranial Magnetic Stimulation) effectively and non-invasively treats depression without inducing systemic side effects.
Brainsway’s technology was cleared by the FDA for treatment of depression patients who did not respond to any number of medication treatments in the current depressive episode. Brainsway’s Deep TMS was enthusiastically received by the international academic community, with 60 clinical trials held in major institutions worldwide.
For more information, please visit brainsway.com.